Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Marizomib: Phase I started

    Triphase Accelerator Corp., San Diego, Calif. Product: Marizomib (NPI-0052) Business: Cancer Molecular target: Proteasome Description: Proteasome inhibitor Indication: Treat grade IV malignant glioma Endpoint: Maximum …

    Published on 5/11/2015
  • OTO-104: Completed Phase II enrollment

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: OTO-104 Business: Other Molecular target: NA Description: Sustained-release dexamethasone gel delivered via intratympanic injection Indication: Treat Menieres …

    Published on 5/11/2015
  • Progenza: Phase I start

    Regeneus Ltd. (ASX:RGS), Pymble, Australia Product: Progenza Business: Autoimmune Molecular target: NA Description: Allogeneic stem cells derived from healthy donor adipose tissues Indication: Treat osteoarthritis (OA) …

    Published on 5/11/2015
  • PTC596: Phase I started

    PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Product: PTC596 Business: Cancer Molecular target: BMI1 polycomb ring finger oncogene (BMI1) Description: BMI1 polycomb ring finger oncogene (BMI1) inhibitor …

    Published on 5/11/2015
  • RHB-105: Completed Phase III enrollment

    RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Product: RHB-105 (formerly Heliconda) Business: Infectious Molecular target: NA Description: Fixed-dose combination of the antibiotics rifabutin and…

    Published on 5/11/2015
  • Ropinirole: Phase III started

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Product: Ropinirole (HP-3000) Business: Neurology Molecular target: Dopamine receptor Description: Transdermal formulation of ropinirole, a dopamine receptor …

    Published on 5/11/2015
  • Staphylococcus lysin: Phase I started

    ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. Product: Staphylococcus lysin (CF-301) Business: Infectious Molecular target: NA Description: Staphylococcal specific lysin protein Indication: Treat Staphylococcus …

    Published on 5/11/2015
  • Strada: Completed Phase II enrollment

    MSI Methylation Sciences Inc., Burnaby, B.C. Product: Strada (MS-195) Business: Neurology Molecular target: NA Description: Formulation of S-adenosyl-L-methionine Indication: Treat major depressive depression (MDD) …

    Published on 5/11/2015
  • TheraSphere: Phase III started

    BTG plc (LSE:BTG), London, U.K. Product: TheraSphere Business: Cancer Molecular target: NA Description: Yttrium-90 glass microspheres used for localized radioembolization therapy Indication: Second-line treatment of …

    Published on 5/11/2015
  • VRS-317: Phase II/III started

    Amunix Operating Inc., Mountain View, Calif. Versartis Inc. (NASDAQ:VSAR), Redwood City, Calif. Product: VRS-317 Business: Endocrine/Metabolic Molecular target: NA Description: Long-acting recombinant human growth …

    Published on 5/11/2015
  • X-82: Phase II started

    Xcovery Holding Co. LLC, West Palm Beach, Fla. Product: X-82 Business: Ophthalmic Molecular target: Vascular endothelial growth factor (VEGF); Platelet derived growth factor receptor (PDGFR) Description: Dual inhibitor …

    Published on 5/11/2015
  • Zoptarelin doxorubicin acetate: Phase III ongoing

    Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS), Quebec City, Quebec Product: Zoptarelin doxorubicin acetate (AEZS-108) (formerly ZEN-008, AN-152) Business: Cancer Molecular target: GnRH/LHRH receptor Description: …

    Published on 5/11/2015
  • 6R-methylenetetrahydrofolate: Phase I/II started

    Isofol Medical AB, Gothenburg, Sweden Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: 6R-methylenetetrahydrofolate (Modufolin) (ISO-901) Business: Other Molecular target: NA Description: Endogenous folate-based …

    Published on 5/4/2015
  • APD421: Phase III started

    Acacia Pharma Ltd., Cambridge, U.K. Product: APD421 (formerly ACA1421) Business: Gastrointestinal Molecular target: Dopamine D2 receptor; Dopamine D3 receptor (DRD3) Description: IV formulation of amisulpride, an off-…

    Published on 5/4/2015
  • Avelumab: Phase III started

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Avelumab (MSB0010718C) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: …

    Published on 5/4/2015
  • Cannabidiol: Phase III started

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Salisbury, U.K. Product: Cannabidiol (Epidiolex) Business: Neurology Molecular target: Cannabinoid receptors Description: Oral liquid formulation of cannabidiol, a …

    Published on 5/4/2015
  • CAR-NKG2D: Phase I started

    Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Product: CAR-NKG2D (CM-CS1) Business: Cancer Molecular target: Killer cell lectin-like receptor subfamily K member 1 (KLRK1) (CD314) (NKG2D) …

    Published on 5/4/2015
  • CCX872: Phase Ib started

    ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif. Product: CCX872 Business: Cancer Molecular target: CC chemokine receptor 2 (CCR2) (CD192) Description: Next-generation oral CC chemokine receptor 2 (CCR2; CD192) …

    Published on 5/4/2015
  • CDX-1401: Phase I/II started

    Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: CDX-1401 Business: Cancer Molecular target: Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1) Description: Fusion protein consisting of a human mAb with …

    Published on 5/4/2015
  • Demcizumab: Phase II started

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Demcizumab (OMP-21M18) Business: Cancer Molecular target: Delta-like 4 (DLL4) Description: Humanized IgG2 mAb against delta-like 4 (DLL4) …

    Published on 5/4/2015
  • Evosyal: Completed Phase III enrollment

    Strathspey Crown Holdings LLC, Newport Beach, Calif. Product: Evosyal, Evolus (DWP-450) Business: Dermatology Molecular target: NA Description: Clostridium botulinum toxin type A neuromodulator Indication: Treat …

    Published on 5/4/2015
  • FR104: Phase I start

    Effimune S.A.S., Nantes, France Product: FR104 Business: Autoimmune Molecular target: CD28 receptor Description: Pegylated monovalent antibody fragment antagonist of CD28 receptor Indication: Treat immune-mediated …

    Published on 5/4/2015
  • Guselkumab: Phase II started

    MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Guselkumab (CNTO 1959) Business: Autoimmune Molecular target: Interleukin-23 (IL-23) Description: …

    Published on 5/4/2015
  • ISTH0036: Phase I started

    Isarna Therapeutics GmbH, Munich, Germany Product: ISTH0036 Business: Ophthalmic Molecular target: Transforming growth factor (TGF) beta 2 (TGFB2) Description: Antisense oligonucleotide targeting transforming growth …

    Published on 5/4/2015
  • Laquinimod: Phase II started

    Active Biotech AB (SSE:ACTI), Lund, Sweden Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Laquinimod (SAIK-MS) Business: Autoimmune Molecular target: S100 calcium binding protein A9 (…

    Published on 5/4/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993